Clinical trials: Pancreatic Fibrosis
Cystic Fibrosis
Muscle Function and Physical Activity in the Modern Era of Cystic Fibrosis
Cystic fibrosis (CF) is characterized by various extrapulmonary manifestations, including altered skeletal muscle function, with both quantitative (e.g. reduced muscle mass) and qualitative (e.g.
- Trial name
- MUCOMUSCLE (NCT06251622)
- Testing
- Volumetric ultrasound of the quadriceps and fitting of an accelerometer
- Where
- France
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Cystic Fibrosis
IL-17 Neutrophils in CF Lung Inflammation
The purpose of this study is to determine whether IL-17 polymorphonuclear leukocytes (PMNs) are central to the disease pathology in CF.
- Trial name
- NCT02025829
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University Hospitals Cleveland Medical Center
Cystic Fibrosis
Miglustat / OGT 918 in the Treatment of Cystic Fibrosis
Cystic fibrosis is a genetic disease caused by mutation of the cystic fibrosis transmembrane conductance regulator (CFTR). The purpose of the study is to investigate the effects of miglustat on CFTR function in cystic fibrosis…
- Trial name
- NCT00537602
- Testing
- miglustat
- Where
- Spain
- Volunteers
- 6 people
- Sponsor
- Actelion
Benign Breast Disease
REGENERA Implant in Excised Non-Malignant Breast Lesions
The purpose of this First-in-Human pilot study is to evaluate the safety and performance of REGENERA breast implant in a selected cohort of patients with non- malignant breast lesions treated with excision or lumpectomy in whom…
- Trial name
- NCT04131972
- Testing
- REGENERA
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Tensive SRL
Cystic Fibrosis
Comparative Analysis of CO2 Monitoring Methods in Patients With CF Undergoing General Anesthesia
Four methods are routinely used to monitor CO2 in patients. End tidal CO2 (EtCO2) is monitored through the endotracheal tube during general anesthesia.
- Trial name
- NCT03734822
- Testing
- End tidal CO2 (EtCO2), Transcutaneous CO2 (TCO2), Capillary CO2 (CapCO2)
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Nationwide Children's Hospital
Cystic Fibrosis
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
The purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype…
- Trial name
- NCT05668741
- Testing
- VX-522 mRNA therapy, IVA
- Where
- 26 sites in United States, Australia and 5 more
- Volunteers
- 26 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Healthy, Cystic Fibrosis
Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics
The study is carried out to evaluate the safety, tolerability and pharmacokinetics of AeroVanc inhalation powder in healthy volunteers, and in patients with cystic fibrosis.
- Trial name
- NCT01537666
- Testing
- AeroVanc, IV vancomycin hydrochloride
- Where
- 2 sites in Australia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Savara Inc.
Cystic Fibrosis
Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF
Cystic fibrosis has many health consequences. A reduction in the ability to perform exercise in patients with CF is related to greater death rates, steeper decline in lung function, and more frequent lung infections.
- Trial name
- CF-AOX (NCT02690064)
- Testing
- Acute Antioxidant, Chronic Antioxidant
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Augusta University
Exocrine Pancreatic Insufficiency: Cystic Fibrosis
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
The purpose of the study is to further evaluate the safety and efficacy of EUR-1008 as compared to Kreon® in the treatment of exocrine pancreatic insufficiency associated with Cystic Fibrosis in subjects 12 years of age and older.
- Trial name
- NCT01641393
- Testing
- EUR-1008 25,000 Units, Kreon 25,000 Units
- Where
- 37 sites in Belgium, Bulgaria and 5 more
- Volunteers
- 96 people
- Sponsor
- Forest Laboratories
Cystic Fibrosis, Liver Fibroses
The Use of Novel Diagnostic Tools to Increase Detection of Early Fibrosis in Cystic Fibrosis Related Liver Disease to Improve Clinical Management
Cystic Fibrosis (CF) is a genetic condition which affects 1 in 2500 newborn infants and is the commonest genetic condition in the UK. 1 in 25 of the white population carry the mutation.
- Conditions
- Cystic Fibrosis, Liver Fibroses, Cystic Fibrosis Liver Disease
- Trial name
- NCT04277819
- Where
- United Kingdom
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Manchester University NHS Foundation Trust
Cystic Fibrosis
Effects of an Early Rehabilitation Program During Hospitalization in Patients With Cystic Fibrosis
Studies demonstrate that exercise increases the maximal oxygen uptake, peak oxygen consumption, reduce effort-induced lactic acid production, and increase skeletal muscle oxidative capacity, as well as psychological aspects such…
- Trial name
- NCT03100214
- Testing
- Exercise, Control
- Where
- Brazil
- Volunteers
- 34 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Cystic Fibrosis
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older
The purpose of the study is to evaluate the long-term safety, tolerability, efficacy, and pharmacodynamics (PD) of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA).
- Trial name
- NCT06460506
- Testing
- ELX/TEZ/IVA, IVA
- Where
- 18 sites in Australia, Canada and 5 more
- Volunteers
- 50 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis, Infection
Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis
This study evaluates the role of AZLI in the treatment of acute pulmonary exacerbations of CF. For consecutive exacerbations patients will receive AZLI + IV Colistin, or two IV anti-pseudomonals.
- Conditions
- Cystic Fibrosis, Infection, Pseudomonas
- Trial name
- AZTEC-CF (NCT02894684)
- Testing
- Aztreonam, Standard Care
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- Liverpool Heart and Chest Hospital NHS Foundation Trust
COPD, Asthma
Evaluation of Regional Ventilation Using 19F MRI of Inert Perfluorinated Gases Mixed With Oxygen
An open label study in 40-60 subjects with diagnosed lung airway disease and in 10-20 normal controls. Each subject will receive PFP as a contrast agent to visualize the airway and alveolar spaces in their lungs using magnetic…
- Conditions
- COPD, Asthma, Cystic Fibrosis, Emphysema
- Trial name
- NCT01710449
- Testing
- perfluorinated gas/oxygen mixture
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Hal C Charles
Cystic Fibrosis, Bronchiectasis
Effect of HFCWO Vests on Spirometry Measurements
The impact of high-frequency chest wall oscillation therapy on spirometry values (Forced Expiratory Volume, Forced Vital Capacity, Peak Expiratory Flow, Forced Expiratory Flow and Tidal Volume is investigated during use of…
- Trial name
- NCT03628456
- Testing
- International Biophysics AffloVest, Hill-Rom Monarch
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- International Biophysics Corporation
Bronchiectasis
Exercise Capacity in Patients With Cystic Fibrosis vs. Non-cystic Fibrosis Bronchiectasis
Introduction: Bronchiectasis is a chronic lung disease in which the underlying condition causes permanent damage to the conducting airways. Bronchiectasis is associated with considerable morbidity and poor quality of life.
- Trial name
- NCT03147651
- Where
- Israel
- Volunteers
- 119 people
- Sponsor
- Rambam Health Care Campus
Cystic Fibrosis
Near Patient Microbial Testing in Cystic Fibrosis
To identify whether home monitoring of multiple physiological parameters and biomarkers in sputum could provide advanced warning of an infective exacerbation or treatment failure before changes in patient-reported symptoms.
- Trial name
- NCT01877707
- Testing
- home monitoring
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- Papworth Hospital NHS Foundation Trust
Cystic Fibrosis (CF), Cystic Fibrosis-related Diabetes
Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)
This multicenter cross-sectional study will include a diverse population of adolescents and adults with CF. The overall Aim is to describe prevalence of diabetes microvascular complications and macrovascular surrogates in people…
- Conditions
- Cystic Fibrosis (CF), Cystic Fibrosis-related Diabetes, Diabetes, Retinopathy
- Trial name
- SPeCTRuM (NCT06837181)
- Testing
- observational study
- Where
- 18 sites in United States
- Volunteers
- 200 people
- Sponsor
- Jaeb Center for Health Research
Cystic Fibrosis
Effect of Sulforaphane in Broccoli Sprouts on Nrf2 Activation
The purpose of this study to investigate the effect of sulforaphane from macerated broccoli sprouts in humans and to evaluate less invasive methods of assessing potential anti-inflammatory drugs in CF.
- Trial name
- NCT01315665
- Testing
- Broccoli sprouts
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Cystic Fibrosis, Cystic Fibrosis-related Diabetes
Performance and Patient Acceptance of a Commercially Available Beverage as Compared to an Oral Glucose Solution for Oral Glucose Tolerance Tests in Cystic Fibrosis (CF) Patients Who Are Screened for CF-related Diabetes.
Rationale: Cystic fibrosis (CF) is an incurable genetic disease that affects the pulmonary system, digestive system, reproductive system and the sweat glands.
- Trial name
- NCT05377502
- Testing
- OGTT
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.